Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|December 21, 2021
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancerZachary Veitch, Domen Ribnikar, Derek Tilley, et al.
Frontiers in Oncology|February 28, 2022
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New ApproachesDavid W Cescon, Kevin Kalinsky, Heather A Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Presentation of nonfinal results of randomized controlled trials at major oncology meetingsChristopher M Booth, Aurélie Le Maître, Keyue Ding, et al.
Advanced Materials (Deerfield Beach, Fla.)|September 14, 2024
Microfluidic Platform for Generating and Releasing Patient-Derived Cancer Organoids with Diverse Shapes: Insight into Shape-Dependent Tumor GrowthSina Kheiri, Ilya Yakavets, Jennifer Cruickshank, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Critical Reviews in Oncology/Hematology|December 10, 2021
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applicationsVasudeva Bhat, Sierra Pellizzari, Alison L Allan, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 16, 2024
Ionizable Drugs Enable Intracellular Delivery of Co-Formulated siRNAKai V Slaughter, Eric N Donders, Michael S Jones, et al.
Journal of Nanobiotechnology|May 18, 2026
Multitargeted nanoparticles inhibit cancer invasion by disrupting cancer-associated fibroblast-tumor cell crosstalk and modulating collagen pattern and EMTLiting Wang, Pei Zhi, Ibrahim Alradwan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 6, 2011
Pharmacogenetic and germline prognostic markers of lung cancerAnne M Horgan, Boming Yang, Abul Kalam Azad, et al.
Cancer Research|May 31, 2019
Integrative Pharmacogenomics Analysis of Patient-Derived XenograftsArvind S Mer, Wail Ba-Alawi, Petr Smirnov, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|December 21, 2021
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancerZachary Veitch, Domen Ribnikar, Derek Tilley, et al.
Frontiers in Oncology|February 28, 2022
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New ApproachesDavid W Cescon, Kevin Kalinsky, Heather A Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Presentation of nonfinal results of randomized controlled trials at major oncology meetingsChristopher M Booth, Aurélie Le Maître, Keyue Ding, et al.
Advanced Materials (Deerfield Beach, Fla.)|September 14, 2024
Microfluidic Platform for Generating and Releasing Patient-Derived Cancer Organoids with Diverse Shapes: Insight into Shape-Dependent Tumor GrowthSina Kheiri, Ilya Yakavets, Jennifer Cruickshank, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Critical Reviews in Oncology/Hematology|December 10, 2021
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applicationsVasudeva Bhat, Sierra Pellizzari, Alison L Allan, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 16, 2024
Ionizable Drugs Enable Intracellular Delivery of Co-Formulated siRNAKai V Slaughter, Eric N Donders, Michael S Jones, et al.
Journal of Nanobiotechnology|May 18, 2026
Multitargeted nanoparticles inhibit cancer invasion by disrupting cancer-associated fibroblast-tumor cell crosstalk and modulating collagen pattern and EMTLiting Wang, Pei Zhi, Ibrahim Alradwan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 6, 2011
Pharmacogenetic and germline prognostic markers of lung cancerAnne M Horgan, Boming Yang, Abul Kalam Azad, et al.
Cancer Research|May 31, 2019
Integrative Pharmacogenomics Analysis of Patient-Derived XenograftsArvind S Mer, Wail Ba-Alawi, Petr Smirnov, et al.
Pageof 14